Straumann Holding AG (STMN) AI Stock Analysis

• Market Cap: CHF14.98B
• Dividend Yield: 1.01%
• Average Volume (3M): 350.69K
• Price to Earnings (P/E): 38.5
• Beta (1Y): 1.35
• Revenue Growth: 4.49%
• EPS Growth: 45.08%
• Country: CH
• Employees: 11,342
• Sector: Healthcare
• Sector Strength: 49
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.66
• Shares Outstanding: 159,455,250
• 10 Day Avg. Volume: 481,104
• 30 Day Avg. Volume: 350,690
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF130.20
• Price Target Upside: 38.60% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 11

• Rating: 68 Neutral
• Price Target: CHF103.00 ▲(9.64% Upside)

Straumann Holding AG's strong financial performance and positive earnings call are offset by technical indicators showing bearish momentum and a high P/E ratio suggesting overvaluation. The company's strategic advancements and growth in key markets are promising, but operational challenges and market conditions need careful monitoring.

Positive Factors

Financial Performance

The company reported a strong start with top-line results beating expectations, indicating robust growth.

Market Expansion

Asia Pacific achieved a historical high in revenue with significant growth, driven by strong market performance.

Market Position

Straumann gained share across core markets, with APAC showing standout double-digit growth in 4Q.

Negative Factors

Consumer Environment

North America experienced modest growth, hindered by a cautious consumer environment.

Economic Outlook

Macro and consumer picture in the US has worsened, potentially affecting Straumann's performance.

Regional Performance

There is concern over sequentially slower North American growth and a lack of clarity on aligner products.

Straumann Holding AG Business Overview & Revenue Model

Company Description

Straumann Holding AG provides tooth replacement and orthodontic solutions worldwide. It researches, develops, manufactures, and supplies dental implants, instruments, CADCAM prosthetics, orthodontic aligners, biomaterials, and digital solutions for use in tooth correction, replacement, and restoration, as well as to prevent tooth loss. The company offers dental implant systems for tissue and bone level; titanium, titanium alloy, ceramic, and mini dental implant systems; and guided and non-guided surgical instruments, as well as implant-borne prosthetics. It provides ceramic healing and screw retained abutments; intraoral scanning solutions; 3D printers; milling machines; and prevention products. In addition, it offers biomaterials, bone substitutes, membranes, biologics, and soft tissue management and oral healing products; digital solutions for dental labs, dentists, and centralized milling centers, as well as materials, third party systems, and guided surgery; surgical instruments comprising surgical and modular cassettes, guided instruments, implant maintenance products, bone block fixation sets, bonerings, titanium pin sets, and other cassettes; and edentulous, pro arch fixed, prosthetic, and mini implant solutions for edentulous patients. Further, it provides esthetic restorations that include ceramic implant monotypes, ceramic implants, abutments, biologics, and other solutions; and Emdogain for wound healing. Further, it offers systems Clear Correct aligners; and training and education services to its customers. The company provides its products to general dentists, specialists, and dental technicians and laboratories, as well as corporate customers, such as distributors, hospitals, universities, and dental service organizations in approximately 100 countries through a network of distribution subsidiaries and partners. Straumann Holding AG was founded in 1954 and is headquartered in Basel, Switzerland.

How the Company Makes Money

Straumann generates revenue primarily through the sale of dental implants and related products, including prosthetics and biomaterials. The company operates a direct sales model as well as through a network of distributors and partners, allowing it to reach a global market. Key revenue streams include the sale of dental implant systems, digital dentistry solutions, and regenerative materials. Additionally, Straumann has established strategic partnerships and collaborations with dental professionals, research institutions, and other industry players to enhance its product offerings and market reach. The company's focus on innovation, evidenced by significant investment in research and development, further contributes to its ability to capture market share and drive revenue growth.

Straumann Holding AG Financial Statement Overview

Summary

Straumann Holding AG is in a strong financial position, with consistent revenue growth and profitability. The company maintains a healthy balance sheet with manageable debt levels. Cash flow is stable, supporting future growth. However, attention should be given to rising operational costs and liabilities.

Income Statement

Straumann Holding AG has demonstrated consistent revenue growth with a solid increase from 2023 to 2024. Gross Profit Margin is strong, indicating effective cost management. However, there is a slight decline in EBIT and EBITDA margins, suggesting rising operating costs or increased competition.

Balance Sheet

The company's balance sheet is stable with a moderate Debt-to-Equity ratio, reflecting balanced leverage. The Return on Equity is healthy, indicating efficient use of equity. The Equity Ratio is solid, showing a strong financial position, although the increase in total liabilities warrants monitoring.

Cash Flow

The cash flow is robust with a stable Free Cash Flow, reflecting the company's good cash generation capacity. There is a slight decline in Operating Cash Flow, which could be a sign of higher operational expenses. The Free Cash Flow to Net Income ratio is favorable, indicating efficient cash management.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.50B	2.41B	2.32B	2.02B	1.43B
Gross Profit	1.78B	1.79B	1.70B	1.53B	1.03B
EBITDA	726.15M	685.07M	685.37M	591.48M	230.45M
Net Income	388.32M	246.07M	434.79M	396.08M	91.28M
Balance Sheet
Total Assets	3.62B	3.40B	3.45B	3.05B	2.62B
Cash, Cash Equivalents and Short-Term Investments	383.07M	413.54M	697.11M	881.50M	632.49M
Total Debt	413.89M	412.35M	705.20M	711.66M	731.66M
Total Liabilities	1.58B	1.56B	1.60B	1.55B	1.41B
Stockholders Equity	2.04B	1.84B	1.85B	1.50B	1.20B
Cash Flow
Free Cash Flow	315.62M	316.61M	220.94M	440.97M	295.34M
Operating Cash Flow	483.39M	503.95M	416.38M	561.94M	377.41M
Investing Cash Flow	-352.62M	-349.33M	-449.84M	-185.20M	-145.64M
Financing Cash Flow	-169.06M	-424.40M	-140.35M	-122.90M	153.33M

Straumann Holding AG Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 93.94
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:STMN, the sentiment is Negative. The current price of 93.94 is below the 20-day moving average (MA) of 98.30, below the 50-day MA of 102.47, and below the 200-day MA of 110.32, indicating a bearish trend. The MACD of -2.71 indicates Positive momentum. The RSI at 39.08 is Neutral, neither overbought nor oversold. The STOCH value of 19.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:STMN.

Straumann Holding AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GALD	71 Outperform	CHF32.57B	99.23		0.11%	6.22%	―
STMN	68 Neutral	CHF14.98B	38.52		1.01%	4.49%	45.08%
SKAN	67 Neutral	CHF1.47B	92.01		0.61%	-3.45%	-49.82%
SOON	61 Neutral	CHF13.13B	25.50		1.93%	6.58%	-10.02%
Sector *	51 Neutral	$7.83B	-0.15	-40.10%	2.29%	21.46%	-2.01%
ALC	―	$40.54B	37.25	4.98%	0.41%	―	―
MED	61 Neutral	CHF1.19B	282.78		―	7.29%	-112.70%

Straumann Holding AG Corporate Events

Straumann Reports Strong Half-Year Results and Confirms 2025 Outlook

Straumann Holding AG reported strong half-year results with sales reaching CHF 1.3 billion, reflecting a 10.2% organic growth. Despite challenges like unfavorable currency developments, the company maintained a robust core EBIT margin and confirmed its 2025 outlook. Key product launches, including the iEXCEL implant system and MIDAS 3D printer, have gained momentum, supporting Straumann’s strategic focus on digital transformation and capacity expansion. The company’s broad-based growth across all regions and business segments underscores its strong market positioning and commitment to innovation.

The most recent analyst rating on (CH:STMN) stock is a Hold with a CHF143.00 price target. To see the full list of analyst forecasts on Straumann Holding AG stock, see the CH:STMN Stock Forecast page.

Straumann Group Announces Webcast for Half-Year Results 2025

Straumann Holding AG announced a webcast for their half-year results 2025, scheduled for August 13, 2025. The event targets investors, financial analysts, and media professionals, providing insights into the company’s business development and offering a platform for questions and answers with the management. This announcement highlights Straumann’s commitment to transparency and engagement with stakeholders, potentially impacting investor confidence and market perception.

The most recent analyst rating on (CH:STMN) stock is a Hold with a CHF143.00 price target. To see the full list of analyst forecasts on Straumann Holding AG stock, see the CH:STMN Stock Forecast page.

Straumann Announces Major Investment in Villeret Amid Strategic Shift to China

Straumann Holding AG has announced a strategic investment of 60 to 80 million CHF in its Villeret site over the next five years to enhance its role as a competence center for innovation and precision manufacturing. This investment will focus on advanced technologies and infrastructure modernization, while also addressing workforce adjustments due to the relocation of production for the Chinese market to a new campus in Shanghai. The move aims to secure competitiveness in China, which accounts for over 15% of Straumann’s global revenue, and ensure long-term growth and market positioning. The changes could affect up to 250 positions in Villeret, with a consultation process underway to explore socially acceptable solutions.

The most recent analyst rating on (CH:STMN) stock is a Buy with a CHF157.00 price target. To see the full list of analyst forecasts on Straumann Holding AG stock, see the CH:STMN Stock Forecast page.